Ono Pharmaceutical Co., Ltd.
Q1 FY2027 Financial Summary (Consolidated)
Ono Pharmaceutical's Q1 FY2027 financial results show net sales of 116.2 billion yen (YoY +0.4%) and net income of 17,631 million yen (YoY +1.0%). Overseas sales are approximately 12.9 billion yen, domestic sales about 87.8 billion yen. Key products include Opdivo and strong performances in overseas markets. The outlook predicts sustained growth.
Key Figures
- Net Sales: 116.2 billion yen (YoY +0.4%)
- Net Income: 17,631 million yen (YoY +1.0%)
- Overseas Sales: about 12.9 billion yen (YoY +約2.9 billion yen)
AI要約
Financial Details and Future Outlook
Sales remain steady, with slight increases in net income. Growth in overseas sales continues to support overall performance, with further overseas expansion expected to be key for revenue growth. R&D expenses are increasing but are positioned as long-term growth investments. Attention is paid to exchange rate effects and new drug launch schedules to build a stable earnings base.
Net Sales Trend
Net Income Trend
Overseas Sales
Ono Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
